Fig. 7: A gene signature targeted by KDM6B inhibition is associated with poor outcome. | Nature Communications

Fig. 7: A gene signature targeted by KDM6B inhibition is associated with poor outcome.

From: KDM6B promotes activation of the oncogenic CDK4/6-pRB-E2F pathway by maintaining enhancer activity in MYCN-amplified neuroblastoma

Fig. 7

a Totally, 149-gene signature was uploaded into R2 genomics analysis program (https://hgserver1.amc.nl/cgi-bin/r2/main.cgi) to find the differentially expressed genes in high-risk neuroblastoma in a cohort dataset (GSE49710) that has 498 neuroblastoma cases, followed by k-means cluster analysis. Risk (red = high risk; green = low risk); MYCN (red = amplification; green = non-amplification); stage (red = stage 4; blue = stage 4S; brown = stage 3; dark green = stage 2, green = stage 1). b, c Kaplan–Meier curve using the Log–Rank method shows the event-free survival and overall survival of four clusters that have differential expression levels of GSK-J4 signature. d, f Kaplan–Meier curve using the Log–Rank method shows the event-free survival and overall survival of clusters 3 and 4 with MNA. e, g Kaplan–Meier curve using the Log–Rank method shows the event-free survival and overall survival of clusters 3 and 4 with high-risk disease. Source data are provided as a “Source data” file.

Back to article page